SCHEMBL3583852

SCHEMBL3583852

CC(C)(C)c1ccc(CN(CCc2cccc(OC(F)(F)F)c2)C(=O)c2cc(Cl)ccc2NCC(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.41
LPAR5 Q9H1C0 1/20 0.41
CNR1 P21554 1/20 0.40
PTGER2 P43116 4/20 0.40
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
CA12 O43570 4/20 0.38
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA4 P22748 4/20 0.38
CA9 Q16790 4/20 0.38
TRPV1 Q8NER1 1/20 0.38
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
P2RX1 P51575 1/20 0.37
C5AR1 P21730 1/20 0.37
HSPH1 Q92598 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583813 0.92 CNR1 (0.41) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3576346 0.91 CNR1 (0.38) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3583799 0.90 CNR1 (0.40) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3581404 0.89 CNR1 (0.43) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3587845 0.85 LPAR1 (0.42) LPAR1LPAR5CNR1CA12CA1
SCHEMBL3586145 0.83 CNR1 (0.42) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3580041 0.83 LPAR1 (0.41) LPAR1LPAR5TRPV1PPARGPPARD
SCHEMBL3569982 0.82 LPAR1 (0.41) LPAR1LPAR5PTGER2CA12CA1
SCHEMBL3577812 0.82 LPAR1 (0.43) LPAR1LPAR5CNR1KDM5AKDM4C
SCHEMBL3579684 0.81 CNR1 (0.40) LPAR1LPAR5CNR1KDM5AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC LPAR1 3429/4885LPAR5 2816/4885CNR1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.